LOADING
Comparing Procter & Gamble (PG) and Pfizer Inc (PFE) across the Consumer Staples and Health Care sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | PG | PFE |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $352.6B | $151.1B |
| P/E Ratio | 22.3 | 19.5 |
| Forward P/E | 20.5 | 9.0 |
| PEG Ratio | 4.10 | 13.77 |
| EPS | $6.75 | $1.36 |
| Revenue Growth (YoY) | 1.5% | -1.2% |
| Profit Margin | 19.3% | 12.4% |
| Return on Equity | 31.6% | 8.9% |
| Dividend Yield | 2.78% | 6.40% |
| Beta | 0.34 | 0.41 |
| 52-Week High | $170.10 | $27.94 |
| 52-Week Low | $136.65 | $19.50 |
| Volume | -- | -- |
Procter & Gamble is the larger company by market capitalization. Pfizer Inc trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Pfizer Inc offers a higher dividend yield for income investors. Procter & Gamble has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.